Abstract
Objective: To investigate the clinical effect of rifapentine and rifampicin in the treatment of pulmonary tuberculosis. Methods: Seventy-two cases of patients with initial treatment of pulmonary tuberculosis who attended the First Hospital Affiliated to Hebei North University from February 2017 to August 2019 were selected. They were randomly divided into observation group and control group, with 36 cases in each group. The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol. The symptom relief, image absorption and adverse reactions were compared between the two groups. Results: The rate of symptom relief was 86.11% in the observation group and 94.44% in the control group, P . The lesion absorption rate was 77.79% in the observation group and 88.89% in the control group, P Conclusion: Rifampicin is superior to rifapentine in clinical symptom relief and lesion absorption, but the incidence of adverse reactions is high.
Highlights
The observation group was treated with isoniazid + rifapentine + ethambutol, while the control group was treated with isoniazid + rifampicin + ethambutol
A total of 33 patients in the control group felt ideal symptom relief, and the total remission rate was 94.44%, which was higher than 8.33% in the observation group
With the globalization of the economy, the widening gap between rich and poor and the increase of rural-urban population mobility, the incidence of tuberculosis is on the rise, which seriously threatens people’s physical and mental health
Summary
Rifampicin [3] [4] is a widely used antibiotic clinical practice. It is the first choice for the treatment of pulmonary tuberculosis. Studies have shown that rifapentine is effective in the treatment of pulmonary tuberculosis [7]. It has little effect on liver function. The aim of this study was to investigate the efficacy of rifapentine and rifampicin on symptom relief, lesion absorption and adverse effects in patients with pulmonary tuberculosis and to assess the efficacy of both
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
